WO2008142162A3 - Pharmaceutical agent for the treatment of fertility and gestation disorders, immunological diseases, and transplantation for use in veterinary medicine, particularly in horses, and methods for the production and treatment monitoring thereof - Google Patents

Pharmaceutical agent for the treatment of fertility and gestation disorders, immunological diseases, and transplantation for use in veterinary medicine, particularly in horses, and methods for the production and treatment monitoring thereof Download PDF

Info

Publication number
WO2008142162A3
WO2008142162A3 PCT/EP2008/056374 EP2008056374W WO2008142162A3 WO 2008142162 A3 WO2008142162 A3 WO 2008142162A3 EP 2008056374 W EP2008056374 W EP 2008056374W WO 2008142162 A3 WO2008142162 A3 WO 2008142162A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
disorders
fertility
transplantation
veterinary medicine
Prior art date
Application number
PCT/EP2008/056374
Other languages
German (de)
French (fr)
Other versions
WO2008142162A2 (en
Inventor
Henry Alexander
Gerolf Zimmermann
Original Assignee
Univ Leipzig
Henry Alexander
Gerolf Zimmermann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leipzig, Henry Alexander, Gerolf Zimmermann filed Critical Univ Leipzig
Priority to EP08759974A priority Critical patent/EP2148694A2/en
Publication of WO2008142162A2 publication Critical patent/WO2008142162A2/en
Publication of WO2008142162A3 publication Critical patent/WO2008142162A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to pharmaceutical agents for the treatment of fertility and pregnancy disorders, and immunological diseases (autoimmune diseases) and transplantation, and a method for the production thereof for use in veterinary medicine, particularly in horses. According to the invention, a protein constituent of equine chorionic gonadotropin (eCG) or a nucleic acid sequence (ecg) coding for a protein constituent of equine chorionic gonadotropin is utilized for the treatment or diagnosis of pregnancy disorders, particularly of fertility disorders, implantation disorders, premature loss of pregnancies, imminent and habitual abortion, premature delivery, and growth retardation, and for the treatment and diagnostics of infectological and immunological diseases, arthritis and ischemia, for facilitating transplantation, for cycle synchronization, and for contraception in veterinary medicine, particularly for perissodactyla, particularly in equines.
PCT/EP2008/056374 2007-05-23 2008-05-23 Pharmaceutical agent for the treatment of fertility and gestation disorders, immunological diseases, and transplantation for use in veterinary medicine, particularly in horses, and methods for the production and treatment monitoring thereof WO2008142162A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08759974A EP2148694A2 (en) 2007-05-23 2008-05-23 Pharmaceutical agent for the treatment of fertility and gestation disorders, immunological diseases, and transplantation for use in veterinary medicine, particularly in horses, and methods for the production and treatment monitoring thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007025107A DE102007025107A1 (en) 2007-05-23 2007-05-23 Medicaments for the treatment of fertility and pregnancy disorders and immunological diseases and transplants for use in veterinary medicine, in particular in horses, and methods of production
DE102007025107.8 2007-05-23

Publications (2)

Publication Number Publication Date
WO2008142162A2 WO2008142162A2 (en) 2008-11-27
WO2008142162A3 true WO2008142162A3 (en) 2009-02-12

Family

ID=39917287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/056374 WO2008142162A2 (en) 2007-05-23 2008-05-23 Pharmaceutical agent for the treatment of fertility and gestation disorders, immunological diseases, and transplantation for use in veterinary medicine, particularly in horses, and methods for the production and treatment monitoring thereof

Country Status (3)

Country Link
EP (1) EP2148694A2 (en)
DE (1) DE102007025107A1 (en)
WO (1) WO2008142162A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102015032660B1 (en) 2015-12-28 2019-05-28 Ouro Fino Saúde Animal Participações S.A. PROCESS OF PRODUCTION OF A RECOMBINANT EQUINE CHORIONIC GONADOTROFIN (RECG): VETERINARY COMPOSITION AND USE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998021238A1 (en) * 1996-11-12 1998-05-22 Teikoku Hormone Mfg. Co., Ltd. Recombinant single-stranded equine chorionic gonadotropin
EP1541168A1 (en) * 2003-12-09 2005-06-15 Akzo Nobel N.V. Method of regulating animal reproduction

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990002757A1 (en) * 1988-09-02 1990-03-22 Integrated Genetics, Inc. Heteropolymeric protein

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998021238A1 (en) * 1996-11-12 1998-05-22 Teikoku Hormone Mfg. Co., Ltd. Recombinant single-stranded equine chorionic gonadotropin
EP0974599A1 (en) * 1996-11-12 2000-01-26 Teikoku Hormone Mfg. Co., Ltd. Recombinant single-stranded equine chorionic gonadotropin
EP1541168A1 (en) * 2003-12-09 2005-06-15 Akzo Nobel N.V. Method of regulating animal reproduction

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DUFRESNE G ET AL: "GENETIC SEQUENCES: HOW ARE THEY PATENTED?", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 22, no. 2, 1 February 2004 (2004-02-01), pages 231 - 232, XP001167185, ISSN: 1087-0156 *
ROY F ET AL: "The negative effect of repeated equine chorionic gonadotropin treatment on subsequent fertility in alpine goats is due to a humoral immune response involving the major histocompatibility complex", BIOLOGY OF REPRODUCTION 1999 US, vol. 60, no. 4, 1999, pages 805 - 813, XP002503143, ISSN: 0006-3363 *
See also references of EP2148694A2 *

Also Published As

Publication number Publication date
EP2148694A2 (en) 2010-02-03
WO2008142162A2 (en) 2008-11-27
DE102007025107A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
JP7163027B2 (en) How to treat infertility
CN104918631A (en) Single dose recombinant bovine FSH after follicular synchronisation
JP6858130B2 (en) Luteal phase oxytocin receptor antagonist therapy for implantation and pregnancy in women receiving assisted reproductive technology
Skidmore Reproduction in the dromedary camel.
Loutradi et al. Evaluation of a transfer medium containing high concentration of hyaluronan in human in vitro fertilization
WO2008142162A3 (en) Pharmaceutical agent for the treatment of fertility and gestation disorders, immunological diseases, and transplantation for use in veterinary medicine, particularly in horses, and methods for the production and treatment monitoring thereof
KR20150139534A (en) Method for scheduling ovulation
JP5139294B2 (en) Pregnancy promoter
Kucuk Intrauterine insemination: is the timing correct?
AboulGheit Pregnancy rates following three different timings of intrauterine insemination for women with unexplained infertility: a randomised controlled trial
Rehman et al. Embryology, Week 2-3
Tur et al. Prevention of multiple pregnancy following IVF in Spain
Swanson et al. Conception and pregnancy
Posada et al. Sperm washing with swim up versus gradients in intrauterine insemination (IUI): results of a prospective randomized study comparing pregnancy rates and costs
Meldrum et al. A pilot study to assess oral contraceptive (OC) pretreatment in women undergoing controlled ovarian hyperstimulation (COH) in ganirelix acetate cycles
Idelevich et al. Mother and Embryo Cross Communication during Conception
Espinoza-Villavicencio et al. Fixed-time artificial insemination and reinsemination of beef cows treated with and without equine chorionic gonadotropin
Huanca López et al. Ovarian response and embryo production in llamas treated with equine chorionic gonadotropin alone or with a progestin-releasing vaginal sponge at the time of follicular wave emergence
Bahrami et al. Comparative study of resynchronization conception rate based on Ovsynch 48 and 56 hour in dairy cow
Barnes Orchestrating the sperm-egg summit
Gil-Salom et al. Intracytoplasmic sperm injection: a treatment for extreme oligospermia
Fucci et al. P-207 Are the time of expansion and morphology of the blastocyst after thawing, assessed by time-lapse technology, decisive for implantation?
Mojtahedi et al. Natural cycle versus modified natural cycle for endometrial preparation in women undergoing frozen-thawed embryo transfer: An RCT
Esfandiari et al. Successful pregnancy following double-frozen embryo transfer in a patient with repeated implantation failure
Reljič et al. Higher live birth and lower pregnancy loss rates in natural compared with artificial cycle protocols for endometrial preparation of frozen blastocyst transfer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08759974

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008759974

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE